Autolus Therapeutics

The company operates from the UK with a registered office in London and additional operations listed across the UK, Germany and the United States, and is publicly traded on Nasdaq.

The company’s core approach is engineering autologous T cells with design features intended to improve tolerability while maintaining anti-tumor activity. Autolus positions its platform around “programming” cellular behavior through receptor design and control elements that shape activation, persistence and safety, aiming to expand the applicability of T cell engagers and CAR-Ts beyond hematologic malignancies.

The lead asset, obecabtagene autoleucel, received U.S. FDA approval on November 8, 2024 for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The approval was based on results from the phase I/II FELIX study, a pivotal dataset for the program.

Regulatory expansion has continued. The company has reported that a European submission was accepted in April 2024, and that a UK marketing authorization application was submitted in July 2024. In reimbursement, NICE recommended the therapy for NHS use in England and Wales in a decision published on November 25, 2025, for adults meeting specified criteria.

Alongside commercialization, Autolus has continued to build governance and execution capacity. Recent disclosures include board appointments such as Ryan Richardson, announced in December 2025, as the company moves from late-stage development into an early commercial profile.